-
公开(公告)号：EP3140397A1
公开(公告)日：2017-03-15
申请号：EP15788723.3
申请日：2015-05-11
IPC分类号： C12N5/0789 , C12N5/02
CPC分类号： C12N5/0692 , A61K35/44 , C12N2501/125 , C12N2501/145 , C12N2501/19 , C12N2501/2303 , C12N2501/998 , C12N2506/1369
摘要： A method for producing a population of cells, enriched for non-adherent endothelial progenitor cells (EPCs), the method comprising culturing an EPC containing population of cells in the presence of interleukin-3 (IL-3), such that a population of cells enriched for non-adherent EPCs is produced.
摘要翻译： 一种用于产生富集非粘附内皮祖细胞（EPCs）的细胞群的方法，所述方法包括在白细胞介素-3（IL-3）存在下培养含有EPC的细胞群，使得细胞群体 生产非附着EPC的富集。
-
公开(公告)号：EP1866647B1
公开(公告)日：2015-04-22
申请号：EP06721313.2
申请日：2006-03-31
发明人： BROWN, Michael, Paul
IPC分类号： C07K16/40 , G01N33/50 , G01N33/573 , G01N33/574
CPC分类号： G01N33/573 , C07K16/40 , G01N33/5011 , G01N33/57488 , G01N2800/52
-
公开(公告)号：EP2791324A1
公开(公告)日：2014-10-22
申请号：EP12856927.4
申请日：2012-12-13
发明人： LOPEZ, Angel , SCHWARZ, Quenten
IPC分类号： C12N5/0793 , C12N5/0797 , A61K45/00 , A61P25/18 , A61P25/28
CPC分类号： A61K35/36 , A61K35/12 , A61K35/30 , A61K35/32 , C12N5/0623
摘要： The present invention relates generally to a method of regenerating the hippocampus in a mammal and agents for use therein. More particularly, the present invention provides a method of regenerating the hippocampus in a mammal by administering a sub-population of neural crest stem cells. The method of the present invention is useful in the treatment of conditions characterised by a defective hippocampus, such as neuropsychiatric disorders.
-
4.发明公开METHOD OF OPTIMIZING THE TREATMENT OF PHILADELPHIA-POSITIVE LEUKEMIA WITH IMATINIB MESYLATE 审中-公开用于优化费城阳性白血病伊马替尼的治疗
公开(公告)号：EP2370078A1
公开(公告)日：2011-10-05
申请号：EP09775407.1
申请日：2009-11-30
IPC分类号： A61K31/506 , A61K35/02
CPC分类号： A61K31/506
摘要： The present invention relates to a method of treating Philadelphia-positive leukemia (Ph+ leukemia), in a particular chronic myeloid leukemia (CML), in a human patient population. More specifically, the present invention pertains to a method of treating Ph+ leukemia, such as CML or Ph+ ALL, in a human patient suffering from Ph+ leukemia comprising the steps of (a) administering a predetermined fixed amount of Imatinib as a free base or in the form of a pharmaceutically acceptable salt thereof to the human patient, (b) collecting at least one blood sample from the patient, e.g. within the first 12 months of treatment, (c) determining the plasma trough level (Cmin) of Imatinib, (d) determining the OCT-1 Activity in the blood sample, and (e) adjusting the dose of Imatinib applied to the individual patient in a manner that an Imatinib Cmin value is achieved in the patient of at least 800 ng/mL, if in step (c) an Imatinib Cmin value of less than 800 ng/mL is found and in step (d) an OCT-1 Activity is found below 6.0 to 10.0 ng/200,000 cells..
-
公开(公告)号：EP2343366A1
公开(公告)日：2011-07-13
申请号：EP10186180.5
申请日：2002-10-04
申请人： Novartis AG , Université Victor Segalen Bordeaux 2 , Oregon Health and Science University , Technische Universität München , University of Heidelberg , Centre Hospitalier Regional Universitaire de Lille , MEDVET SCIENCE PTY. LTD.
发明人： Barthe, Christophe , Branford, Susan , Corbin, Amie , Druker, Brian Jay , Duyster, Justus , Hochhaus, Andreas , Hughes, Timothy , Kreil, Sebastian , Leguay, Thibaut , Mahon, Francois-Xavier , Marit, Gerald , Mueller, Martin , Peschel, Christian , Preudhomme, Claude , Roche Lestienne, Catherine , Rudzki, Zbigniew
CPC分类号： C12N9/1205
摘要： The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, lle333, Phe317, Met318, Met351, Glu355, Glu359, lle360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.
摘要翻译： 本发明涉及分离的多肽，其包含功能激酶结构域，所述功能激酶结构域包含天然人Abl激酶结构域的氨基酸序列或其基本上相似的序列，其中至少一个选自Met244，Leu248，Gly250，Glu252，Tyr253， Val256，Glu258，Phe311，Ile333，Phe317，Met318，Met351，Glu355，Glu359，Ile360，His361，Leu370，Asp381，Phe382，His396，Ser417，Glu459和Phe486被另一个氨基酸置换，所述突变的功能激酶结构域对 通过N- [4-甲基-3-（4-吡啶-3-基 - 嘧啶-2-基氨基） - 苯基] -4-（4-甲基 - 哌嗪-1-基甲基） - 苯甲酰胺抑制其酪氨酸激酶活性 涉及使用这样的多肽筛选抑制这些多肽的酪氨酸激酶活性的化合物，编码这些多肽的核酸分子，包含这些核酸分子的重组载体和宿主细胞，以及涉及这样的多肽 核酸分子 用于筛选抑制这些多肽的酪氨酸激酶活性的化合物。
-
公开(公告)号：EP2343365A1
公开(公告)日：2011-07-13
申请号：EP10186114.4
申请日：2002-10-04
申请人： Novartis AG , Université Victor Segalen Bordeaux 2 , Oregon Health and Science University , Technische Universität München , University of Heidelberg , Centre Hospitalier Regional Universitaire de Lille , MEDVET SCIENCE PTY. LTD.
发明人： Barthe, Christophe , Branford, Susan , Corbin, Amie , Druker, Brian Jay , Duyster, Justus , Hochhaus, Andreas , Hughes, Timothy , Kreil, Sebastian , Leguay, Thibaut , Mahon, Francois-Xavier , Marit, Gerald , Mueller, Martin , Peschel, Christian , Preudhomme, Claude , Roche Lestienne, Catherine , Rudzki, Zbigniew
CPC分类号： C12N9/1205
摘要： The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-y(methyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.
摘要翻译： 本发明涉及分离的多肽，其包含功能激酶结构域，所述功能激酶结构域包含天然人Abl激酶结构域的氨基酸序列或其基本上相似的序列，其中至少一个选自Met244，Leu248，Gly250，Glu252，Tyr253， Val256，Glu258，Phe311，Ile313，Phe317，Met318，Met351，Glu355，Glu359，Ile360，His361，Leu370，Asp381，Phe382，His396，Ser417，Glu459和Phe486被另一个氨基酸置换，所述突变的功能激酶结构域对 通过N- [4-甲基-3-（4-吡啶-3-基 - 嘧啶-2-基氨基） - 苯基] -4-（4-甲基 - 哌嗪-1-基）（甲基） - 苯甲酰胺或其盐的用途，涉及这些多肽用于筛选抑制这些多肽的酪氨酸激酶活性的化合物，编码这些多肽的核酸分子，包含此类核酸分子的重组载体和宿主细胞以及用途 的这种核酸分子 用于筛选抑制这些多肽的酪氨酸激酶活性的化合物。
-
公开(公告)号：EP2290056A3
公开(公告)日：2011-06-01
申请号：EP10174534.7
申请日：2002-10-04
申请人： Novartis AG , Centre Hospitalier Regional Universitaire de Lille , MEDVET SCIENCE PTY. LTD. , Oregon Health & Science University , Technische Universität München , University of Heidelberg , Université Victor Segalen Bordeaux 2
发明人： Barthe, Christophe , Branford, Susan , Corbin, Amie , Druker, Brian Jay , Duyster, Justus , Hochhaus, Andreas , Hughes, Timothy , Kreil, Sebastian , Leguay, Thibaut , Mahon, François-Xavier , Marit, Gérald , Müller, Martin , Peschel, Christian , Preudhomme, Claude , Roche Lestienne, Catherine , Rudzki, Zbigniew
CPC分类号： C12N9/1205
摘要： The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.
-
-
公开(公告)号：EP2082235A1
公开(公告)日：2009-07-29
申请号：EP07815354.1
申请日：2007-10-11
IPC分类号： G01N33/574 , C12Q1/68 , G01N33/68
CPC分类号： G01N33/57496 , C12Q1/6886 , C12Q2600/158 , G01N2800/52
摘要： The present invention relates generally to a method of screening for a neoplastic cell in a subject. More particularly, the present invention provides a method of screening for both viable neoplastic cells and, still further, cytotoxin induced neoplastic cell death by detecting the level of expression of La protein and/or gene by a cellular population in said subject or in a biological sample derived from said subject. The method of the present invention is useful in a range of applications including, but not limited to, diagnosing, prognosing or assessing a neoplastic condition, monitoring the progression of such a condition, assessing the effectiveness of a therapeutic agent or therapeutic regime and predicting the likelihood of a subject either progressing to a more advanced disease state or entering a remissive state. The present invention also provides diagnostic agents useful for detecting La protein and/or nucleic acid molecules.
-
公开(公告)号：EP1720971A1
公开(公告)日：2006-11-15
申请号：EP05700111.7
申请日：2005-01-21
IPC分类号： C12M1/26
CPC分类号： C12M33/02
摘要： A streaker device for streaking a microbial inoculum for single colonies on the surface of a solid growth medium. The streaking device has a row of spaced apart contact surfaces for contact with the surface of the solid growth medium. The spaced apart contact surfaces are resiliently flexibly supported by a common support member so as to accommodate variations in depth of growth medium. The spaced apart contact surfaces may be provided on lowermost part of axially curved portions of plastics straps, that are angled backwardly. It is found that formation of a single band can give separation into single colonies. Also provided is an automatic streaking apparatus.
摘要翻译： 用于在固体生长培养基表面上单菌落划线的微生物接种物的划痕器。 拖尾装置具有用于与固体生长培养基的表面接触的一排间隔开的接触表面。 间隔开的接触表面由共同的支撑构件弹性地柔性地支撑，以适应生长介质深度的变化。 间隔开的接触表面可以设置在向后成角度的塑料带的轴向弯曲部分的最下部分上。 发现单一带的形成可以分离成单个菌落。 还提供了自动划线装置。
-
-
-
-
-
-
-
-
-
搜索结果
107 条记录 (耗时 0.034 秒)
